Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

40 results about "Pharmaceutical Databases" patented technology

Computer Chinese medicine prognosis disease inferring and prescription derivation system based on mathematics of Yin-yang and five elements

A computer Chinese medicine prognosis disease inferring and prescription derivation system based on mathematics of Yin-yang and five elements comprises an existing disease symptom input module, a prognosis disease deducing-judging module, a medicament selecting module and a medicament database, wherein the medicament database stores the name, nature and taste, functions, mainly-treated symptoms, reference doses of each medicament as well as application-treatment correlation of each medicament with each visceral organ and symptom; the existing disease symptom input module provides an existing disease selection menu, so that a user can input a corresponding diseased visceral organ and the symptom by clicking the options of the existing disease selection menu according to the existing diagnostic result; the prognosis disease deducing-judging module transforms the diseased visceral organ and the symptom into existing disease semantic logic operators and conducts derivation operation thereon to obtain the un-diseased visceral organ and symptom expressed by prognosis disease semantic logic operators; and the medicament selection module obtains the diseased and un-diseased visceral organs and symptoms and selects medicaments according to the application-treatment correlation of each medicament with each visceral organ and symptom. The system realizes the standardization and automation of prognosis disease inferring and prescription derivation.
Owner:NORTHWEST UNIV

Method and system for calculation and graphical presentation of drug-drug or drug-biological process interactions on a smart phone, tablet or computer

A method and system is provided for visualization and pictorial presentation to a user of possible interactions between a prospective drug that is being considered for prescribing to a person and that person's genotype. Genetic information of the person that can affect the manner in which a drug acts on a molecular, physiological or biological function of the body or a tissue, or a manner in which a drug is being metabolized, absorbed, excreted or otherwise eliminated from the body or a tissue by the body or tissue systems, is entered into a computerized device. The computerized device conducts a search of a drug database for drugs that have known interactions with the entered genetic information, and assigns a numeric value to each of a plurality of drugs, either in aggregate, as a class, or individually, in order to quantify the nature, strength and direction of each interaction. The computer sends the assigned numeric values to the computer's output module for their visual presentation to a user as a graph including a panel of columns, or other geometrical structures, whose geometrical characteristics correspond to the assigned numeric values of each drug, in order to facilitate the prospective drug selection by a prescriber on the basis of the totality of drug-gene and/or drug-drug interactions presented to the user as a visual graph.
Owner:BASKYS ANDRIUS

Medicament combination predicting method based on medicament similarity network data

The invention discloses a medicament combination predicting algorithm based on a medicament similarity network, wherein the algorithm mainly settles a problem of low accuracy of a medicament combination predicting result in prior art. The medicament combination predicting algorithm is characterized by comprising steps of downloading data from a medicament database, constructing the medicament similarity network; downloading data from a medicament combination database; obtaining a network importance score based on medicament combination data and the medicament similarity network; obtaining a total set of random walk paths of multiple networks by means of a biased random walk algorithm, and training the total set of the random walk paths for obtaining a medicament node characteristic vector; training the medicament combination data and the medicament node characteristic vector by means of a random forest model, and obtaining a medicament combination predicting model; and inputting medicament pair data into the medicament combination predicting model, obtaining a medicament pair score, and using the medicament pair with score which is higher than 0.5 as a cooperation medicament combination. The medicament combination predicting algorithm improves medicament combination predicting accuracy and can be used for predicting the cooperative medicament combination candidate.
Owner:XIDIAN UNIV

Screening method for precise therapeutics of liver-metastasis triple-negative breast cancer

The invention provides a screening method for precise therapeutics of the liver-metastasis triple-negative breast cancer. The method comprises the following steps: acquiring RNAs from the liver-metastasis tissue of patients with the liver-metastasis triple-negative breast cancer and further acquiring the gene information of the RNAs; finding out genes with high expression exceeding normal liver gene expression from the gene information; carrying out data mining on the high-expression genes so as to obtain the gene expression profile of breast cancer liver-metastasis tissue of the patients andthe gene expression profile of primary ductal breast cancer; subjecting the gene expression profiles to topology analysis so as to obtain corresponding genomic imprinting expression; and finding out drugs targeting to the genomic imprinting expression from a drug database and screening out precise therapeutics for the liver-metastasis triple-negative breast cancer of the patients according to thelaws of Chinese government. The screening method provided by the invention is clear and simple and is easy to operate; and the screened therapeutics are high in precision, good in prognosis effect andlow in side-effect and bring good news to patients with the liver-metastasis triple-negative breast cancer.
Owner:SHANGHAI XINCHEN MEDICAL TECH CO LTD

Precision medicine for treating and preventing suicidality

ActiveUS20200318188A1Facilitate and prevent behaviorMitigating suicidalityMicrobiological testing/measurementMedical automated diagnosisDrug DatabasesPatient stratification
The present disclosure relates generally to discovery of novel compounds involved in the treatment and prevention of suicidality by bioinformatics drug repurposing using novel genes expression biomarkers involved in suicidality. Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for suicidality. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in preventing and treating suicidality. These methods include computer-assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. Detailed herein are methods using a universal approach, in everybody, as well as personalized approaches by gender, and by diagnosis. The discovery describes compounds for use in everybody (universal), as well as personalized by gender (males, females), diagnosis (bipolar, depression), gender and diagnosis combined (male bipolar, male depression), male PTSD, male SZ/SZA), and subtypes of suicidality (high anxiety, low mood, combined (affective), and high psychosis (non-affective). Also disclosed are methods for identifying which subjects should be receiving which treatment, using genes expression biomarkers for patient stratification and measuring response to treatment. The disclosure also relates to algorithms, universal and personalized by gender and diagnosis. The algorithms combine biomarkers as well as clinical measures for suicidality and for mental state, in order to identify subjects who are at risk of committing suicide, as well as to track responses to treatments. The disclosure further relates to determining subtypes of suicidality. Such subtypes may delineate groups of individuals that are more homogenous in terms of biology, behavior, and response to treatment.
Owner:INDIANA UNIV RES & TECH CORP +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products